2,617 reports of this reaction
3.1% of all NINTEDANIB reports
#9 most reported adverse reaction
VOMITING is the #9 most commonly reported adverse reaction for NINTEDANIB, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 2,617 FDA adverse event reports linking NINTEDANIB to VOMITING. This represents approximately 3.1% of all 85,660 adverse event reports for this drug.
NINTEDANIB has an overall safety score of 85 out of 100. Patients taking NINTEDANIB who experience vomiting should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VOMITING is moderately reported among NINTEDANIB users, representing a notable but not dominant share of adverse events.
In addition to vomiting, the following adverse reactions have been reported for NINTEDANIB:
The following drugs have also been linked to vomiting in FDA adverse event reports:
VOMITING has been reported as an adverse event in 2,617 FDA reports for NINTEDANIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
VOMITING accounts for approximately 3.1% of all adverse event reports for NINTEDANIB, making it a notable side effect.
If you experience vomiting while taking NINTEDANIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.